Skip to main content
SpringerLink
Log in

Bevacizumab added to single-agent CT not cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 US dollars

Reference

  • Wysham WZ, et al. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. Gynecologic Oncology : 10 Mar 2017. Available from: URL: http://doi.org/10.1016/j.ygyno.2017.02.039

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bevacizumab added to single-agent CT not cost effective. PharmacoEcon Outcomes News 775, 15 (2017). https://doi.org/10.1007/s40274-017-3879-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3879-x

Search

Navigation